-
Priorities for addressing mental health conditions and substance use disorders in prisons in sub-Saharan Africa: expert consensus from a Delphi panel Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-15
Helen E Jack, Aish Lovett, Hiwot Weldemariam, Atalay Alem, Serge Dali, Sakios Muduma, Murugi Micheni, Letitia Pienaar, Charlene Sunkel, Zoë Senter, Maryia Shaban, Lydia Chwastiak, Sarah Walker, Adegboyega OgunwalePeople who are incarcerated in Africa are not a focus of global mental health research, and incarceration is absent from many international mental health guidelines. Given the dearth of knowledge and services, priorities for research and practice should be established. The Delphi method was used to identify priority challenges related to mental health and substance use disorders among people who are
-
Setting the research agenda for mental health Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-15
No Abstract
-
Priovi appears to be a valuable digital tool for patients with borderline personality disorder Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-15
Vivian B PenderNo Abstract
-
Accurate prevalence estimates needed for youth common mental disorders Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-15
Patrick D McGorry, Eóin Killackey, Eric Chen, Andrew ChanenNo Abstract
-
Accurate prevalence estimates needed for youth common mental disorders – Authors' reply Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-15
Ellie M Robson, Susan M SawyerNo Abstract
-
Does ADHD treatment inefficacy question its diagnostic validity? Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-15
Gin S Malhi, Kinga Szymaniak, Erica BellNo Abstract
-
Does ADHD treatment inefficacy question its diagnostic validity? – Authors' reply Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-15
Edoardo G Ostinelli, Andrea Cipriani, Samuele CorteseNo Abstract
-
Bipolar depression management needs randomised controlled trial evidence Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-15
Chien Cheng, Tien-Wei Hsu, Yu-Chen Kao, Mu-Hong Chen, Chih-Sung LiangNo Abstract
-
Bipolar depression management needs randomised controlled trial evidence – Authors' reply Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-15
Cagatay Ermis, Heidi Taipale, Jari TiihonenNo Abstract
-
Correction to Lancet Psychiatry 2025; 12: e3–6 Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-15
The Lancet Psychiatry. Thanks to our peer reviewers for 2024. The Lancet Psychiatry 2025; 12: e3–6—In this Comment, Ángel Aguilera Martín should have been included in the list of peer reviewers for 2024. This correction has been made to the online version as of April 15, 2025.
-
John M Kane: investigator, collector, and innovator Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-15
Jules MorganNo Abstract
-
A digital therapeutic for people with borderline personality disorder in Germany (EPADIP-BPD): a pragmatic, assessor-blind, parallel-group, randomised controlled trial Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-15
Nele Assmann, Gitta Jacob, Anja Schaich, Thomas Berger, Tristan Zindler, Linda Betz, Stefan Borgwardt, Arnoud Arntz, Eva Fassbinder, Jan Philipp KleinBackgroundFewer than 25% of patients with borderline personality disorder (BPD) receive guideline-adherent psychotherapy. Digital therapeutics can help reduce this gap. Therefore, we tested the effectiveness and safety of priovi, a digital therapeutic for BPD. MethodsWe conducted a pragmatic, assessor-blind, parallel-group, randomised controlled trial, recruiting patients with BPD, according to DSM-5
-
Understanding Placebo Mechanisms to Reduce Attrition in Psychiatric Trials. JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-16
Nathan T M Huneke,Samuele Cortese,Marco Solmi -
Cognitive Behavior Therapy for Mental Disorders in Adults JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-16
Pim Cuijpers, Mathias Harrer, Clara Miguel, Marketa Ciharova, Davide Papola, Djordje Basic, Cristina Botella, Ioana Cristea, Nino de Ponti, Tara Donker, Ellen Driessen, Pamela Franco, Irene Gómez-Gómez, Jessica Hamblen, Noelia Jiménez-Orenga, Eirini Karyotaki, Aaron Keshen, Jake Linardon, Emma Motrico, Minoo Matbouriahi, Olga M. Panagiotopoulou, Rory A. Pfund, Constantin Yves Plessen, Heleen RiperImportanceCognitive behavior therapy (CBT) is a first-line treatment for most mental disorders. However, no meta-analytic study has yet integrated the results of randomized clinical trials on CBT across different disorders, using uniform methodologies and providing a complete overview of the field.ObjectiveTo examine the effect sizes of CBT for 4 anxiety disorders, 2 eating disorders, major depression
-
Issues in Clinical Trial Design—Lessons From the FDA’s Rejection of MDMA JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-16
Samuel T. Wilkinson, Gerard SanacoraThis Viewpoint explores potential justifications underlying the US Food and Drug Administration (FDA)’s rejection of methylenedioxymethamphetamine (MDMA) as a treatment for posttraumatic stress disorder, including lack of blinding and issues around the integrity of relevant clinical trials.
-
Negative Effects During Placebo Treatment JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-16
Tom Bschor, Josephine Unger, Lea Nagel, Guido Schwarzer, Christopher BaethgeImportanceAnalyzing effects within placebo groups allows for transdiagnostic comparisons, as placebo is the only substance systematically studied across all major psychiatric diagnoses. Recently, the study team meta-analytically showed that improvement under placebo varies across major psychiatric diagnoses. However, comprehensive transdiagnostic comparisons of negative effects under placebo (nocebo
-
Lessons Learned From Drug Decriminalization Remedies in British Columbia. JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-14
John F Kelly -
Book Review: Then I Am Myself the World: What Consciousness Is and How to Expand It Book Review: Then I Am Myself the World: What Consciousness Is and How to Expand It. By KochChristof. New York: Basic Books, 2024, 274 pp., $30 hardcover. J. Am. Psychoanal. Assoc. (IF 1.4) Pub Date : 2025-04-12
Jamey Hecht -
Book Review: The Pole Book Review: The Pole. By CoetzeeJ. M.New York: Liveright, An Imprint of W.W. Norton & Company, 2023, 176 pp., $17.99 paperback. J. Am. Psychoanal. Assoc. (IF 1.4) Pub Date : 2025-04-12
Robert C. Abrams -
Recommendations for defining treatment outcomes in major psychiatric disorders using real-world data Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-10
Elise Koch, Sophie Smart, Guðmundur Einarsson, Anders Kämpe, Lina Jonsson, Maris Alver, Matthew Iveson, Andreas Göteson, Antonio F Pardiñas, Ida E Sønderby, Kevin S O'Connell, Qingqin Li, Yi Lu, Hreinn Stefánsson, Kári Stefánsson, Heather Whalley, Mikael Landén, Michael C O'Donovan, Knut Smerud, Gerard R Dawson, Ole A AndreassenAlthough information from real-world data can be used to identify factors that aid treatment choice, there are no guidelines for the use of such data. The aim of this Review is to summarise and evaluate definitions of treatment outcomes for antidepressants, antipsychotics, and mood stabilisers when using real-world data, and to suggest standards for the field. Given that no standards for the use of
-
Persistency in Somatic Symptoms: A Sign of Stagnation in Stimulus- Response Process. Psychother. Psychosom. (IF 16.3) Pub Date : 2025-04-11
Vedat Şar,Görkem Ayas -
-
Automating the Addiction Behaviors Checklist for Problematic Opioid Use Identification JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-09
Angus H. Chatham, Eli D. Bradley, Vanessa Troiani, Donielle L. Beiler, Parker Christy, Lori Schirle, Sandra Sanchez-Roige, David C. Samuels, Alvin D. JefferyImportanceIndividuals whose chronic pain is managed with opioids are at high risk of developing an opioid use disorder. Electronic health records (EHR) allow large-scale studies to identify a continuum of problematic opioid use, including opioid use disorder. Traditionally, this is done through diagnostic codes, which are often unreliable and underused.ObjectiveTo determine whether regular expressions
-
Convergence of Cannabis and Psychosis on the Dopamine System JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-09
Jessica Ahrens, Sabrina D. Ford, Betsy Schaefer, David Reese, Ali R. Khan, Philip Tibbo, Rachel Rabin, Clifford M. Cassidy, Lena PalaniyappanImportanceDespite evidence that individuals with a cannabis use disorder (CUD) are at elevated risk of psychosis and that the neurotransmitter dopamine has a role in psychosis, the mechanism linking cannabis use and psychosis remains unclear.ObjectiveTo use neuromelanin-sensitive magnetic resonance imaging (MRI), referred to as the neuromelanin-MRI signal, a practical, proxy measure of dopamine function
-
Clinician Suicide Risk Assessment for Prediction of Suicide Attempt in a Large Health Care System JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-09
Kate H. Bentley, Chris J. Kennedy, Pratik N. Khadse, Jasmin R. Brooks Stephens, Emily M. Madsen, Matthew J. Flics, Hyunjoon Lee, Jordan W. Smoller, Taylor A. BurkeImportanceClinical practice guidelines recommend suicide risk screening and assessment across behavioral health settings. The predictive accuracy of real-world clinician assessments for stratifying patients by risk of future suicidal behavior, however, remains understudied.ObjectiveTo evaluate routine clinical suicide risk assessment for prospectively predicting suicide attempt.Design, Setting, and
-
Dialectical Behaviour Therapy to Treat Emotion Dysregulation in Autistic adults without Intellectual Disability: A Randomised Controlled Trial. Psychother. Psychosom. (IF 16.3) Pub Date : 2025-04-09
Doha Bemmouna,Emmett Rabot,Romain Coutelle,François Lefebvre,Sébastien Weibel,Luisa WeinerINTRODUCTION Emotion dysregulation is prevalent in autistic adults without intellectual disability whereby it has been associated with heightened non-suicidal self-injury and suicidal behaviours. Dialectical behaviour therapy (DBT) has shown to be feasible and preliminary findings suggest that it might reduce emotion dysregulation in this population. Yet studies evaluating the efficacy of DBT in this
-
Clinical and Neurophysiological Effects of Robotically-Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Depression. Psychother. Psychosom. (IF 16.3) Pub Date : 2025-04-09
Luke J Hearne,Lachlan Webb,Robin Cash,Conor Robinson,Philip E Mosley,Joanna Ng,Simon T Thwaites,Simon Issa,Jessica Miller,Nga Yan Tse,Andrew Zalesky,Bjorn Burgher,Luca CocchiINTRODUCTION Repetitive transcranial magnetic stimulation (rTMS) of the left dorsolateral prefrontal cortex (DLPFC) is an established treatment for refractory major depressive disorder (MDD), but treatment outcomes vary substantially from person to person. Recent evidence suggests that incorporating neuroimaging-based targeting may help improve clinical outcomes. Here, we report the initial clinical
-
Long-Read Genome Sequencing in Clinical Psychiatry: RFX3 Haploinsufficiency in a Hospitalized Adolescent With Autism, Intellectual Disability, and Behavioral Decompensation. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-04-09
Milad Mortazavi,Sergey Batalov,Jerica Lenberg,Corrine Blucher,Aisha Omorodion,Daniel Helbling,Lucita Van Der Kraan,Zaira Bezares-Orin,Arivudainambi Ramalingam,Matthew N Bainbridge,Jonathan Sebat,Aaron D Besterman -
Trends in Prescription Stimulant, Opioid, and Benzodiazepine Use and Diversion in U.S. Adolescents. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-04-09
Sean Esteban McCabe,Emily Pasman,Timothy E Wilens,Ty S Schepis,Vita V McCabe,Jason A Ford,John Jardine,Philip T Veliz -
Factors that affect the resilience of young adults to depression: a systematic review Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-08
Linda Theron, Dov J Stekel, Jan Höltge, Olufunmilayo I Fawole, Diane T Levine, Zainab Mai-Bornu, Kassa Maksudi, Olanrewaju Olaniyan, Caradee Y Wright, Michael UngarDepression among young people (aged 18–29 years) transitioning to adulthood is becoming more widespread. Knowing which factors in which systems co-enable resilience to depression is crucial, but there is no comprehensive synthesis of the physiological, psychological, social, economic, institutional, cultural, and environmental system factors associated with no or minimal emerging adult depression,
-
Brexpiprazole for the treatment of adolescent schizophrenia Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-07
Maria RogdakiNo Abstract
-
Efficacy and safety of brexpiprazole in adolescents with schizophrenia: a multicountry, randomised, double-blind, placebo-controlled, phase 3 trial with an active reference Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-07
Caroline Ward PhD, Prof Milica Pejović Milovančević MD, Eva Kohegyi MD, Nanco Hefting MSc, Catherine Aurang BA, Dalei Chen PhD, Klaus Groes Larsen PhD, Mary Hobart PhD, Prof Christoph U Correll MDNew treatment options are needed for adolescent schizophrenia, partly due to an unfavourable risk–benefit profile of current options. This trial aimed to evaluate the short-term efficacy and safety of brexpiprazole in adolescents with schizophrenia.
-
Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-06
Luis C Farhat PhD, Alice Lannes MD, Cinzia Del Giovane PhD, Valeria Parlatini PhD, Miguel Garcia-Argibay PhD, Edoardo G Ostinelli MD, Anneka Tomlison PhD, Zheng Chang PhD, Prof Henrik Larsson PhD, Cristiano Fava PhD, François Montastruc PhD, Prof Andrea Cipriani PhD, Prof Alexis Revet PhD, Prof Samuele Cortese PhDConcerns about the cardiovascular safety of medications used for the treatment of attention-deficit hyperactivity disorder (ADHD) remain. We aimed to compare the effects of pharmacological treatments for ADHD on haemodynamic values and electrocardiogram (ECG) parameters in children, adolescents, and adults.
-
Cardiovascular effects of ADHD medications Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-06
Steven R PliszkaNo Abstract
-
Functional vs Structural Cortical Deficit Pattern Biomarkers for Major Depressive Disorder JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-04
Peter Kochunov, Bhim M. Adhikari, David Keator, Daniel Amen, Si Gao, Nicole R. Karcher, Demetrio Labate, Robert Azencott, Yewen Huang, Hussain Syed, Hongjie Ke, Paul M. Thompson, Danny J. J. Wang, Braxton D. Mitchell, Jessica A. Turner, Theo G.M. van Erp, Neda Jahanshad, Yizhou Ma, Xiaoming Du, William Burroughs, Shuo Chen, Tianzhou Ma, Jair C. Soares, L. Elliot HongImportanceMajor depressive disorder (MDD) is a severe mental illness characterized more by functional rather than structural brain abnormalities. The pattern of regional homogeneity (ReHo) deficits in MDD may relate to underlying regional hypoperfusion. Capturing this functional deficit pattern provides a brain pattern–based biomarker for MDD that is linked to the underlying pathophysiology.ObjectiveTo
-
Esketamine Combined With SSRI or SNRI for Treatment-Resistant Depression JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-04
Antonio Del Casale, Sara Spirito, Jan Francesco Arena, Saskia Preissner, Marina Borro, Giovanna Gentile, Martina Nicole Modesti, Robert Preissner, Stefano Ferracuti, Maurizio SimmacoImportanceTreatment-resistant depression (TRD) remains a critical challenge in psychiatry, with limited effective options. Esketamine, a rapid-acting antidepressant, is usually combined with a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI), but comparative evidence of these combinations’ effectiveness in real-world settings is sparse.ObjectiveTo
-
Demographic Gaps and Digital Innovations in Therapy Trends. JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-02
Qiang Xie -
Refining Social Determinants of Suicide Risk Research. JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-02
Ping-I Lin,Nawar Nayeem,Erick Messias -
Demographic Gaps and Digital Innovations in Therapy Trends-Reply. JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-02
Mark Olfson -
Should Inflammation Be a Specifier for Major Depression in the DSM-6? JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-02
Manish K. Jha, Marion Leboyer, Carmine M. Pariante, Andrew H. MillerThis Viewpoint discusses the opportunity to include inflammatory biomarkers as specifiers for major depression in the upcoming Sixth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-6).
-
Genetic Confounding in the Association Between Traumatic Brain Injury and Mental Disorder or Suicide JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-02
Søren Dinesen Østergaard, Jessica Mundy, Alisha Silvia Mercedes Hall, Katherine L. MuslinerImportanceTraumatic brain injury is common and occurs across all ages. Observational studies have shown that traumatic brain injury is associated with a wide range of mental disorders and suicide. Whether these associations represent a causal effect is, however, difficult to establish, and confounding by genetic liability for mental disorder may play a substantial role.ObjectiveTo investigate whether
-
Variability Rather Than Means? Harnessing the Adversary to Advance Precision Psychiatry. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-04-01
Raquel E Gur,David R Roalf,Daniel H Wolf,Ruben C Gur -
Kynurenic Acid and Promotion of Activity-Dependent Synapse Elimination in Schizophrenia. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-04-01
Funda Orhan,Susmita Malwade,Neda Khanlarkhani,Asimenia Gkogka,Angelika Langeder,Oscar Jungholm,Marja Koskuvi,Šárka Lehtonen,Lilly Schwieler,Kent Jardemark,Jari Tiihonen,Jari Koistinaho,Sophie Erhardt,Göran Engberg,Samudyata Samudyata,Carl M SellgrenOBJECTIVE Schizophrenia is a neurodevelopmental disorder characterized by an excessive loss of synapses. Kynurenic acid (KYNA), a neuroactive metabolite of tryptophan along the kynurenine pathway, can induce schizophrenia-related phenotypes in rodents, and clinical studies have revealed elevated KYNA levels in the CNS of individuals with schizophrenia. However, the factors that cause elevated KYNA
-
A Call to Psychiatrists: Deprescription of Unnecessary Anticholinergic Medications in Schizophrenia Must Start Now. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-04-01
K N Roy Chengappa,Jessica M Gannon,Yash B Joshi -
What Do Four Decades of Research Tell Us About the Association Between Childhood Adversity and Psychosis: An Updated and Extended Multi-Level Meta-Analysis. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-04-01
Lan Zhou,Iris E C Sommer,Pengyuan Yang,Lev Sikirin,Jim van Os,Richard P Bentall,Filippo Varese,Marieke J H BegemannOBJECTIVE Estimating the current association between childhood adversity and the risk of psychosis is crucial for prevention and intervention. We provided an updated synthesis of evidence from the past four decades, expanded the available data by investigating a broad array of adversity subtypes, and explored sex differences and the age of psychosis onset as relevant factors. METHODS We searched PubMed
-
Psychotic Disorders and Schizophrenia: Treatment, Risk, Brain Alterations, and Mechanisms. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-04-01
Ned H Kalin -
When the Bow Breaks: Are We Ever Going to Prevent Childhood Adversity? Am. J. Psychiatry (IF 15.1) Pub Date : 2025-04-01
C Neill Epperson -
Long-Term Antipsychotic Use and the Benefit-to-Harm Balance: More on the Risk of Relapse. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-04-01
Robin Emsley -
An Update on the Use of Neuromodulation Strategies in the Treatment of Schizophrenia. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-04-01
Nicholas H Neufeld,Daniel M BlumbergerThe field of neuromodulation has evolved tremendously and now includes a vast array of interventions utilizing different technologies that span electrical, magnetic, and ultrasound forms of stimulation. The evolution of interventions holds the promise of fewer adverse effects and a noninvasive approach, increasing the scale at which these interventions may be offered in hospital and community settings
-
INTEGRATE: international guidelines for the algorithmic treatment of schizophrenia Lancet Psychiatry (IF 30.8) Pub Date : 2025-03-31
Robert A McCutcheon PhD, Toby Pillinger PhD, Ioana Varvari MRCPsych, Sean Halstead MD, Olatunde O Ayinde MS, Nicolás A Crossley PhD, Prof Christoph U Correll MD, Prof Margaret Hahn PhD, Prof Oliver D Howes DM, Prof John M Kane MD, Thomas Kabir PhD, Åsa Konradsson-Geuken PhD, Prof Belinda Lennox DM, Christy Lai Ming Hui PhD, Prof Susan L Rossell PhD, Marco Solmi PhD, Prof Iris E Sommer MD PhD, HeidiSchizophrenia is a mental illness involving multiple symptom domains and is often associated with substantial physical health comorbidities. Guidelines exist, but these tend to be country-specific and are often missing a concise yet comprehensive algorithmic approach. From May 1, 2023, to Jan 1, 2025, International Guidelines for Algorithmic Treatment (INTEGRATE) authors from all UN regions collaborated
-
Exploring the Black Box: What Happens During Brief Concentrated Exposure and Response Prevention for Obsessive-Compulsive Disorder? Psychother. Psychosom. (IF 16.3) Pub Date : 2025-03-28
Franziska Miegel,Jakob Scheunemann,Saskia Pampuch,Josephine Schultz,Bjarne Hansen,Kristen Hagen,Jürgen Gallinat,Antonia Zapf,Amir H Yassari,Lena JelinekBACKGROUND Brief concentrated exposure and response prevention (cERP) has shown promise as an efficacious treatment for obsessive-compulsive disorder (OCD). with higher response and remission rates compared to the first-line treatment. However, the mechanisms driving this success remain unclear. METHODS This longitudinal study included 56 patients with OCD who underwent cERP (Bergen four-day treatment;
-
India's mental health budget 2025 needs urgent reform Lancet Psychiatry (IF 30.8) Pub Date : 2025-03-27
Sheikh Shoib, Ilham Zaidi, Miyuru Chandradasa, Sujita Kumar Kar, Fahimeh SaeedNo Abstract
-
Reevaluating the brain disease model of addiction Lancet Psychiatry (IF 30.8) Pub Date : 2025-03-25
Chrysanthi Blithikioti, Eiko I Fried, Emiliano Albanese, Matt Field, Ioana A CristeaThe brain disease model of addiction has dominated public and scientific discourse on addiction (termed substance use disorder [SUD] in the DSM-5) over the past 3 decades. The model framed addiction as a chronic and relapsing brain disease caused by structural and functional brain alterations. The purpose of this model was purportedly dual, as both an aetiological theory and a tool to reduce stigma
-
Caring for Patients With Severe Anorexia Nervosa—A Capacity Evaluation Cannot Save Us JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-26
Emily G. Holmes, Jane A. Hartsock, Amy S. MartinThis Viewpoint discusses assessing decision-making capacity in patients with severe anorexia nervosa and why a multidisciplinary approach is preferred.
-
Prescription Stimulant Prescribing, Nonmedical Use, and Shortages JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-26
Joshua P. Rising, Robert M. CaliffThis Viewpoint discusses developing better evidence about appropriate use of stimulants, understanding and reducing nonmedical use of these medications, and responding to shortages.
-
Effective Components of Collaborative Care for Depression in Primary Care: An Individual Participant Data Meta-Analysis. JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-26
Hannah Schillok,Jochen Gensichen,Maria Panagioti,Jane Gunn,Lukas Junker,Karoline Lukaschek,Caroline Jung-Sievers,Philipp Sterner,Lukas Kaupe,Tobias Dreischulte,Mohammed K Ali,Enric Aragonès,David B Bekelman,Birgit Herbeck Belnap,Robert M Carney,Lydia A Chwastiak,Peter A Coventry,Karina W Davidson,Maria L Ekstrand,Alison Flehr,Susan Fletcher,Lars P Hölzel,Klaas Huijbregts,Viswanathan Mohan,Vikram PatelImportance Collaborative care is a multicomponent intervention for patients with chronic disease in primary care. Previous meta-analyses have proven the effectiveness of collaborative care for depression; however, individual participant data (IPD) are needed to identify which components of the intervention are the principal drivers of this effect. Objective To assess which components of collaborative
-
Exploring the impact of Metacognitive Interpersonal Therapy on borderline personality disorder: a retrospective observational study using a latent transition analysis of symptoms and functional changes over 12 months. Psychother. Psychosom. (IF 16.3) Pub Date : 2025-03-26
Matteo Aloi,Antonio Semerari,Giulio Amadei,Ilaria Bucci,Livia Colle,Giuseppe Nicolò,Ilaria Riccardi,Cristina Segura-Garcia,Antonino CarcioneINTRODUCTION Borderline personality disorder (BPD) is marked by emotional instability, interpersonal dysfunction, and high comorbidity, posing significant treatment challenges. Metacognitive Interpersonal Therapy (MIT) targets core features of BPD, including metacognitive impairments and emotional dysregulation. This study uses Latent Transition Analysis (LTA) to assess changes in BPD symptoms and
-
20 Years of Aberrant Salience in Psychosis: What Have We Learned? Am. J. Psychiatry (IF 15.1) Pub Date : 2025-03-26
Philip R Corlett,Kurt M FraserTwenty years ago Shitij Kapur's "Psychosis as a state of aberrant salience" captured the attention of clinicians and cognitive and behavioral neuroscientists. It has become the de facto way of talking about delusion formation in labs and clinics. Here, evidence for this theory is critically evaluated in consideration of evolving data since its publication. A particular focus is placed on its specific
-
A Call to Action: Evidence-Based Contingency Management. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-03-26
Carla J Rash,Michael McDonell,Tyler Erath,Sara Parent,Richard Rawson,Sarah Wattenberg -
Psychiatric Genetics in Clinical Practice: Essential Knowledge for Mental Health Professionals. Am. J. Psychiatry (IF 15.1) Pub Date : 2025-03-26
Aaron D Besterman,Mohamed A Alnor,Mauricio Castaño,Lynn E DeLisi,Dorothy E Grice,Falk W Lohoff,Christel M Middeldorp,Daniel J Müller,Diego Quattrone,John Nurnberger,Erika L Nurmi,David A Ross,Takahiro Soda,Thomas G Schulze,Brett Trost,Elisabet Vilella,Chloe X Yap,Gwyneth Zai,Daniel Moreno-De-LucaOBJECTIVE The authors provide recommendations on incorporating recent advances in psychiatric genetics into clinical practice for mental health clinicians. METHOD The International Society for Psychiatric Genetics Education Committee met monthly to come to a consensus on priority topics in psychiatric genetics. Topics were then assigned to small teams of subspecialty experts to summarize the current